Compass Therapeutics, Inc. recently appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective January 1, 2026, adding deep oncology ...
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy. Predictive ...
Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed. The study ...
From statistical support to study management and specimen banking to data analysis, COMPASS is comprised of a robust team at Fred Hutch Cancer Center. COMPASS promotes scientific excellence in ...
BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback